Author:
Jin L E,Wang M,Yang S-T,Yang Y,Galvin V C,Lightbourne T C,Ottenheimer D,Zhong Q,Stein J,Raja A,Paspalas C D,Arnsten A F T
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Psychiatry and Mental health,Molecular Biology
Reference69 articles.
1. Li ML, Hu XQ, Li F, Gao WJ . Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end? Prog Neuropsychopharmacol Biol Psychiatry 2015; 60: 66–76.
2. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA . The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008; 22: 308–322.
3. Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC . Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treat 2014; 2014: 758212.
4. Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry 2014; 14: 351.
5. Kinon BJ, Millen BA, Zhang L, McKinzie DL . Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 2015; 78: 754–762.
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献